HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon

This article was originally published in The Rose Sheet

Executive Summary

Net sales slipped 1.3% to $1.23 bil. in the third quarter, and net earnings fell 39.5% to $41.5 mil, the company announced Oct. 22. Through nine months, net sales rose 2.8% to $3.56 bil., while net earnings dropped 40.6% to $121.9 mil. Avon attributed the sales decrease in part to international economies. "Very strong results" in the U.S., U.K., Brazil and Central Europe were partially offset by a decline in Avon's Russian operations and "continued weakness" in some Asian economies. In the cosmetic, toiletry and fragrance category, Anew Night Force and Anew Day Force did particularly well, Avon said. The number of worldwide active representatives increased 11% in the third quarter. In 1997, the number of worldwide active representatives totaled approximately 2.6 mil

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel